Biotech | April 29, 2022
Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
It is expanding the diagnostics business footprint in North East India
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Revolution Aspire CT System is manufactured at the company’s new plant launched under the government’s Production Linked Incentives (PLI) Scheme
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Secretary, Department of Pharmaceuticals and Union Health Secretary Chair a Panel Discussion on the theme 'Indian Pharma Vision 2047'
Subscribe To Our Newsletter & Stay Updated
